Solstice Oncology
A clinical-stage immunotherapy company is advancing an engineered CTLA-4 antibody for earlier cancer treatment.
$225MSeries A
ParticipantCP
Canaan Partners
Activity from announced rounds
Activity in this selectionberkeley-frontier-fund-33c1357a
- Rounds participated in
- 1
- Confirmed lead rounds
- 0 All roles disclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $225M 1 disclosed · full round size, not this investor’s share